JP2016516428A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516428A5 JP2016516428A5 JP2016509098A JP2016509098A JP2016516428A5 JP 2016516428 A5 JP2016516428 A5 JP 2016516428A5 JP 2016509098 A JP2016509098 A JP 2016509098A JP 2016509098 A JP2016509098 A JP 2016509098A JP 2016516428 A5 JP2016516428 A5 JP 2016516428A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- engineered polypeptide
- pal
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 claims description 16
- 230000002378 acidificating effect Effects 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- 241000078013 Trichormus variabilis Species 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 2
- 102200091761 rs33926449 Human genes 0.000 claims 128
- 229920001184 polypeptide Polymers 0.000 claims 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims 50
- 108090000765 processed proteins & peptides Proteins 0.000 claims 50
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 claims 37
- 238000006467 substitution reaction Methods 0.000 claims 19
- 125000000539 amino acid group Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 230000017854 proteolysis Effects 0.000 claims 6
- 102220626287 RUN domain-containing protein 3B_L47M_mutation Human genes 0.000 claims 4
- 230000035945 sensitivity Effects 0.000 claims 4
- 201000011252 Phenylketonuria Diseases 0.000 claims 3
- 238000004220 aggregation Methods 0.000 claims 3
- 230000002776 aggregation Effects 0.000 claims 3
- 102200047300 c.127C>A Human genes 0.000 claims 3
- 230000003197 catalytic effect Effects 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 239000007897 gelcap Substances 0.000 claims 2
- 239000006187 pill Substances 0.000 claims 2
- 102220214356 rs1060501305 Human genes 0.000 claims 2
- 102220232156 rs370120266 Human genes 0.000 claims 2
- 102220062177 rs786202861 Human genes 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 102220546945 ASNSD1 upstream open reading frame protein_Q39A_mutation Human genes 0.000 claims 1
- 108090000673 Ammonia-Lyases Proteins 0.000 claims 1
- 102000004118 Ammonia-Lyases Human genes 0.000 claims 1
- 102000005367 Carboxypeptidases Human genes 0.000 claims 1
- 108010006303 Carboxypeptidases Proteins 0.000 claims 1
- 108090000317 Chymotrypsin Proteins 0.000 claims 1
- 102220473686 DNA repair protein RAD50_G45D_mutation Human genes 0.000 claims 1
- 102220595765 Glutathione peroxidase 6_Q58H_mutation Human genes 0.000 claims 1
- 102220511169 HMG box-containing protein 1_G20S_mutation Human genes 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 102200108120 c.116C>T Human genes 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229960002376 chymotrypsin Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002797 proteolythic effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 102200050840 rs11568438 Human genes 0.000 claims 1
- 102220029635 rs146867923 Human genes 0.000 claims 1
- 102200153342 rs1555937077 Human genes 0.000 claims 1
- 102220223774 rs375605948 Human genes 0.000 claims 1
- 102220023192 rs387907509 Human genes 0.000 claims 1
- 102220277622 rs550945533 Human genes 0.000 claims 1
- 102220014966 rs61732490 Human genes 0.000 claims 1
- 102220032317 rs76914224 Human genes 0.000 claims 1
- 102200042086 rs8192687 Human genes 0.000 claims 1
- 102220125344 rs886043940 Human genes 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 239000002478 γ-tocopherol Substances 0.000 claims 1
- 102100029989 SHC SH2 domain-binding protein 1 Human genes 0.000 description 5
- 102000030789 Histidine Ammonia-Lyase Human genes 0.000 description 4
- 108700006308 Histidine ammonia-lyases Proteins 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 101900027613 Nostoc punctiforme Phenylalanine ammonia-lyase Proteins 0.000 description 2
- 241000192520 Oscillatoria sp. Species 0.000 description 2
- 241001575211 Rivularia <snail> Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361813586P | 2013-04-18 | 2013-04-18 | |
| US61/813,586 | 2013-04-18 | ||
| US201361897932P | 2013-10-31 | 2013-10-31 | |
| US61/897,932 | 2013-10-31 | ||
| PCT/US2014/034500 WO2014172541A2 (en) | 2013-04-18 | 2014-04-17 | Engineered phenylalanine ammonia lyase polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018149210A Division JP2018166524A (ja) | 2013-04-18 | 2018-08-08 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016516428A JP2016516428A (ja) | 2016-06-09 |
| JP2016516428A5 true JP2016516428A5 (enExample) | 2017-11-30 |
| JP6637410B2 JP6637410B2 (ja) | 2020-01-29 |
Family
ID=51729192
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509098A Expired - Fee Related JP6637410B2 (ja) | 2013-04-18 | 2014-04-17 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| JP2018149210A Withdrawn JP2018166524A (ja) | 2013-04-18 | 2018-08-08 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| JP2020138453A Active JP7129715B2 (ja) | 2013-04-18 | 2020-08-19 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| JP2020138454A Withdrawn JP2020185017A (ja) | 2013-04-18 | 2020-08-19 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| JP2022169038A Pending JP2022183356A (ja) | 2013-04-18 | 2022-10-21 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018149210A Withdrawn JP2018166524A (ja) | 2013-04-18 | 2018-08-08 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| JP2020138453A Active JP7129715B2 (ja) | 2013-04-18 | 2020-08-19 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| JP2020138454A Withdrawn JP2020185017A (ja) | 2013-04-18 | 2020-08-19 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| JP2022169038A Pending JP2022183356A (ja) | 2013-04-18 | 2022-10-21 | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
Country Status (27)
| Country | Link |
|---|---|
| US (17) | US9611468B2 (enExample) |
| EP (3) | EP2986722B1 (enExample) |
| JP (5) | JP6637410B2 (enExample) |
| KR (1) | KR102218930B1 (enExample) |
| CN (2) | CN109486803B (enExample) |
| AU (2) | AU2014253900C1 (enExample) |
| CA (1) | CA2909719C (enExample) |
| CY (1) | CY1121891T1 (enExample) |
| DK (2) | DK3521423T3 (enExample) |
| EA (1) | EA034034B1 (enExample) |
| ES (2) | ES2729048T3 (enExample) |
| HR (1) | HRP20190928T1 (enExample) |
| HU (2) | HUE043549T2 (enExample) |
| IL (1) | IL242067B (enExample) |
| LT (1) | LT2986722T (enExample) |
| MX (1) | MX366196B (enExample) |
| MY (1) | MY193198A (enExample) |
| NZ (1) | NZ713396A (enExample) |
| PE (1) | PE20151775A1 (enExample) |
| PH (1) | PH12015502412B1 (enExample) |
| PL (1) | PL2986722T3 (enExample) |
| PT (1) | PT2986722T (enExample) |
| RS (1) | RS58802B1 (enExample) |
| SG (1) | SG11201508598YA (enExample) |
| SI (1) | SI2986722T1 (enExample) |
| SM (1) | SMT201900315T1 (enExample) |
| WO (1) | WO2014172541A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2986722T3 (pl) | 2013-04-18 | 2019-10-31 | Codexis Inc | Skonstruowane polipeptydy amoniakoliazy fenyloalaniny |
| EP3145536B1 (en) * | 2014-04-16 | 2021-10-27 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3882259B1 (en) | 2015-05-13 | 2026-01-28 | Synlogic Operating Company, Inc. | Bacteria engineered to reduce hyperphenylalaninemia |
| CN106636048A (zh) * | 2016-12-14 | 2017-05-10 | 江南大学 | 一株酶活提高的苯丙氨酸脱氨酶突变体 |
| CN106755160B (zh) * | 2017-01-17 | 2019-08-02 | 湖州颐辉生物科技有限公司 | 一种组氨酸解氨酶及其用途 |
| AU2018217495B2 (en) * | 2017-02-13 | 2021-03-04 | Codexis, Inc. | Engineered phenylalanine ammonia lyase polypeptides |
| CN110914288B (zh) * | 2017-05-27 | 2023-05-05 | 宁波酶赛生物工程有限公司 | 工程化醛缩酶多肽及其应用 |
| EP3642221A1 (en) | 2017-06-21 | 2020-04-29 | Synlogic Operating Company, Inc. | Bacteria for the treatment of disorders |
| EP3807409A4 (en) * | 2018-06-12 | 2022-08-03 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| EP3820833A4 (en) * | 2018-07-12 | 2022-08-03 | Codexis, Inc. | MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES |
| JP7780186B2 (ja) * | 2018-10-29 | 2025-12-04 | コデクシス， インコーポレイテッド | 操作されたｄｎａポリメラーゼバリアント |
| AU2019397401A1 (en) * | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| WO2021168060A1 (en) * | 2020-02-19 | 2021-08-26 | Trustees Of Tufts College | Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained |
| WO2021188819A1 (en) * | 2020-03-20 | 2021-09-23 | Synlogic Operating Company, Inc. | Microorganisms engineered to reduce hyperphenylalaninemia |
| WO2022146718A1 (en) * | 2020-12-31 | 2022-07-07 | Synlogic Operating Company, Inc. | Microorganisms engineered to reduce hyperphenylalaninemia |
| AU2022279241A1 (en) * | 2021-05-21 | 2023-11-30 | Syntis Bio, Inc. | Engineered methionine gamma lyase variants |
| CN114015636B (zh) * | 2021-12-08 | 2023-09-29 | 天地壹号饮料股份有限公司 | 重组醋酸菌及其制备方法和应用 |
| CN114457151B (zh) * | 2022-01-27 | 2024-06-11 | 宁夏医科大学总医院 | 一种用于检测苯丙氨酸羟化酶基因突变的检测试剂盒及其检测方法 |
| CN117417925A (zh) * | 2022-07-18 | 2024-01-19 | 浙江泽科塔生物医药有限公司 | Pal变体、包含该pal变体的药物组合物以及用于制备该pal变体的方法 |
| CN115518691B (zh) * | 2022-10-14 | 2023-11-21 | 天津大学 | 一种具有类漆酶活性的人工酶及制备方法和应用 |
| CN115873837A (zh) * | 2022-11-18 | 2023-03-31 | 安徽盈科生物科技有限公司 | 高表达的新型的苯丙氨酸解氨酶 |
| CN116478975B (zh) * | 2023-06-16 | 2023-09-01 | 苏州优信合生技术有限公司 | 高活性苯丙氨酸解氨酶突变体及其表达菌株 |
| JPWO2025063255A1 (enExample) * | 2023-09-19 | 2025-03-27 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US603344A (en) | 1898-05-03 | Trough for well-curbs | ||
| US753653A (en) | 1903-09-14 | 1904-03-01 | American Car & Foundry Co | Hopper-bottom car. |
| DK75593D0 (enExample) * | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| CA2191718A1 (en) | 1994-06-03 | 1995-12-14 | Randy M. Berka | Phosphonyldipeptides useful in the treatment of cardiovascular diseases |
| ATE294871T1 (de) | 1994-06-30 | 2005-05-15 | Novozymes Biotech Inc | Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| EP1717322B1 (en) | 1997-01-17 | 2012-07-18 | Codexis Mayflower Holdings, LLC | Evolution of whole cells and organisms by recursive sequence recombination |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| IL136574A0 (en) | 1997-12-08 | 2001-06-14 | California Inst Of Techn | A method for forming a polynucleotide of desired properties |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
| US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US7702464B1 (en) | 2001-08-21 | 2010-04-20 | Maxygen, Inc. | Method and apparatus for codon determining |
| US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
| JP2002534965A (ja) | 1999-01-19 | 2002-10-22 | マキシジェン， インコーポレイテッド | 所望の特徴を有する文字ストリング、ポリヌクレオチドおよびポリペプチドを作製するための方法 |
| AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
| US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| US6519065B1 (en) | 1999-11-05 | 2003-02-11 | Jds Fitel Inc. | Chromatic dispersion compensation device |
| AU4964101A (en) | 2000-03-30 | 2001-10-15 | Maxygen Inc | In silico cross-over site selection |
| US6967097B2 (en) | 2000-07-24 | 2005-11-22 | Pcbu Services, Inc. | Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same |
| EP2315145B1 (en) | 2002-03-01 | 2015-11-25 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional biomolecules |
| US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| US7747391B2 (en) | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| WO2003078583A2 (en) | 2002-03-09 | 2003-09-25 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
| US8003356B2 (en) | 2004-04-20 | 2011-08-23 | E. I. Du Pont De Nemours And Company | Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH |
| AU2005286763A1 (en) | 2004-09-17 | 2006-03-30 | Biomarin Pharmaceutical, Inc. | Variants and chemically-modified variants of phenylalanine ammonia-lyase |
| EP1869174B1 (en) | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) * | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| WO2008069958A2 (en) * | 2006-12-01 | 2008-06-12 | The Salk Institute For Biological Studies | Substrate switched ammonia lyases and mutases |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| ES2705694T3 (es) | 2008-06-13 | 2019-03-26 | Codexis Inc | Método de síntesis de variantes de polinucleótidos |
| US8383346B2 (en) | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| EP4062928A3 (en) | 2010-02-04 | 2022-11-30 | BioMarin Pharmaceutical Inc. | Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia |
| CA2815341A1 (en) | 2010-11-05 | 2012-05-10 | Basf Plant Science Company Gmbh | Methods for increasing yield and fine chemical production in plants |
| WO2012122333A1 (en) | 2011-03-08 | 2012-09-13 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Microbial conversion of glucose to styrene and its derivatives |
| US20130005012A1 (en) | 2011-06-23 | 2013-01-03 | Phytogene, Inc. | Enzymatic system for monomer synthesis |
| PL2986722T3 (pl) | 2013-04-18 | 2019-10-31 | Codexis Inc | Skonstruowane polipeptydy amoniakoliazy fenyloalaniny |
-
2014
- 2014-04-17 PL PL14784792T patent/PL2986722T3/pl unknown
- 2014-04-17 SI SI201431165T patent/SI2986722T1/sl unknown
- 2014-04-17 SG SG11201508598YA patent/SG11201508598YA/en unknown
- 2014-04-17 NZ NZ713396A patent/NZ713396A/en not_active IP Right Cessation
- 2014-04-17 CN CN201811343013.3A patent/CN109486803B/zh not_active Expired - Fee Related
- 2014-04-17 KR KR1020157032841A patent/KR102218930B1/ko not_active Expired - Fee Related
- 2014-04-17 AU AU2014253900A patent/AU2014253900C1/en not_active Ceased
- 2014-04-17 MY MYPI2015002575A patent/MY193198A/en unknown
- 2014-04-17 SM SM20190315T patent/SMT201900315T1/it unknown
- 2014-04-17 EP EP14784792.5A patent/EP2986722B1/en active Active
- 2014-04-17 HU HUE14784792A patent/HUE043549T2/hu unknown
- 2014-04-17 CA CA2909719A patent/CA2909719C/en active Active
- 2014-04-17 JP JP2016509098A patent/JP6637410B2/ja not_active Expired - Fee Related
- 2014-04-17 LT LTEP14784792.5T patent/LT2986722T/lt unknown
- 2014-04-17 EA EA201591995A patent/EA034034B1/ru not_active IP Right Cessation
- 2014-04-17 ES ES14784792T patent/ES2729048T3/es active Active
- 2014-04-17 CN CN201480035201.3A patent/CN105324483B/zh not_active Expired - Fee Related
- 2014-04-17 RS RS20190709A patent/RS58802B1/sr unknown
- 2014-04-17 US US14/255,539 patent/US9611468B2/en not_active Expired - Fee Related
- 2014-04-17 DK DK19163814.7T patent/DK3521423T3/da active
- 2014-04-17 HR HRP20190928TT patent/HRP20190928T1/hr unknown
- 2014-04-17 DK DK14784792.5T patent/DK2986722T3/da active
- 2014-04-17 WO PCT/US2014/034500 patent/WO2014172541A2/en not_active Ceased
- 2014-04-17 EP EP19163814.7A patent/EP3521423B1/en active Active
- 2014-04-17 PT PT14784792T patent/PT2986722T/pt unknown
- 2014-04-17 HU HUE19163814A patent/HUE055899T2/hu unknown
- 2014-04-17 MX MX2015014662A patent/MX366196B/es active IP Right Grant
- 2014-04-17 ES ES19163814T patent/ES2890955T3/es active Active
- 2014-04-17 PE PE2015002177A patent/PE20151775A1/es unknown
- 2014-04-17 EP EP21186620.7A patent/EP3971288A1/en not_active Withdrawn
-
2015
- 2015-10-14 IL IL242067A patent/IL242067B/en active IP Right Grant
- 2015-10-19 PH PH12015502412A patent/PH12015502412B1/en unknown
-
2017
- 2017-02-13 US US15/431,491 patent/US10160963B2/en active Active
- 2017-09-29 US US15/720,060 patent/US10487319B2/en active Active
- 2017-09-29 US US15/720,198 patent/US10144924B2/en active Active
-
2018
- 2018-08-08 JP JP2018149210A patent/JP2018166524A/ja not_active Withdrawn
- 2018-10-22 US US16/166,359 patent/US10358639B2/en active Active
- 2018-10-31 US US16/176,896 patent/US10294468B2/en active Active
- 2018-10-31 US US16/176,986 patent/US10494623B2/en active Active
-
2019
- 2019-04-19 US US16/389,203 patent/US10717974B2/en not_active Expired - Fee Related
- 2019-06-26 CY CY20191100659T patent/CY1121891T1/el unknown
- 2019-10-14 US US16/601,278 patent/US11130947B2/en not_active Expired - Fee Related
- 2019-10-14 US US16/601,173 patent/US10640759B2/en active Active
- 2019-10-14 US US16/601,228 patent/US11136571B2/en not_active Expired - Fee Related
- 2019-10-15 US US16/601,993 patent/US10870843B2/en not_active Expired - Fee Related
- 2019-10-15 US US16/653,061 patent/US10941391B2/en not_active Expired - Fee Related
- 2019-11-29 AU AU2019272057A patent/AU2019272057B2/en not_active Ceased
-
2020
- 2020-03-09 US US16/813,207 patent/US10975367B2/en not_active Expired - Fee Related
- 2020-03-26 US US16/831,698 patent/US11401515B2/en active Active
- 2020-08-19 JP JP2020138453A patent/JP7129715B2/ja active Active
- 2020-08-19 JP JP2020138454A patent/JP2020185017A/ja not_active Withdrawn
- 2020-09-02 US US17/009,925 patent/US11913045B2/en active Active
-
2021
- 2021-04-01 US US17/220,684 patent/US20210222146A1/en not_active Abandoned
-
2022
- 2022-10-21 JP JP2022169038A patent/JP2022183356A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014253900B2 (en) | Engineered phenylalanine ammonia lyase polypeptides | |
| Ling et al. | Preparation and identification of novel inhibitory angiotensin-I-converting enzyme peptides from tilapia skin gelatin hydrolysates: Inhibition kinetics and molecular docking | |
| JP2020505942A5 (enExample) | ||
| JP7429907B2 (ja) | セリアックスプルー病を治療するための組成物および方法 | |
| JP2010522540A5 (enExample) | ||
| JP2009525757A5 (enExample) | ||
| CN104736552B (zh) | 用于预防或治疗心血管疾病的、包含对血管紧张素‑i转换酶表现出抑制活性的肽作为活性成分的药物组合物 | |
| SA03240005B1 (ar) | مركبات ثلاثي ببتيد مثبط لالتهاب الكبد c | |
| JP2017221201A5 (enExample) | ||
| JP2004504032A5 (enExample) | ||
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| CN116589533A (zh) | 南极磷虾小分子活性肽及其制备方法和应用 | |
| JP2007529204A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2014529399A5 (enExample) | ||
| JP2020530282A5 (enExample) | ||
| JP2025121900A5 (enExample) | ||
| JP2023090702A5 (enExample) | ||
| CN114292311B (zh) | 胰脂肪酶抑制肽及其应用 | |
| EP2600894B1 (en) | Modified hepatitis c virus proteins | |
| CN101612386B (zh) | 鹿血活性肽在制备降血压药物及保健品中的应用 | |
| JP2010138133A (ja) | 微細藻類スピルリナ由来の血圧降下ペプチド及びその製造方法 | |
| JP2004537284A5 (enExample) | ||
| CN114773431A (zh) | 龙须菜ace抑制肽、制备方法及应用 | |
| CN115974971A (zh) | 四种来源于小米蛋白的血管紧张素转移酶抑制剂及其应用 |